Marksans Pharma, 524404, MARKSANS Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

11,693.89
30.73
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

11,012.77
0.31%
4.74

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

10.58
13.93
13.46

EBITDA CAGR (%)

10 Years
5 Years
3 Years

10.06
18.99
12.11

PAT CAGR (%)

10 Years
5 Years
3 Years

11.11
21.80
19.34

P:E (Median)

8 Years
5 Years
3 Years

15.50
14.74
21.45

P:BV (Average)

8 Years
5 Years
3 Years

2.84
3.16
3.40

EV:EBITDA (Average)

8 Years
5 Years
3 Years

11.52
10.73
12.77

Earnings Forecasts:

(Updated: 06-06-2025)

Description 2024 2025 2026 2027
Adj EPS 6.92 8.4 10.52 12.92
P/E Ratio 37.28 30.71 24.52 19.97
Revenue 2177 2623 3129 3708
EBITDA 459 529 652 792
Net Income 314 381 478 586
ROA 12.9 12.9 12.3 12.4
P/B Ratio 9.56 4.74 4.01 3.35
ROE 16.47 16.8 17.4 18
FCFF 47 65 294 449
FCFF Yield 0.43 0.59 2.68 4.09
Net Debt -457 -383 -920 -1290
BVPS 26.98 54.44 64.4 77

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var%
Net Sales 299.36 225.20 32.93% 311.87 241.36 29.21% 308.63 204.67 50.79% 254.53 182.04 39.82%
Expenses 248.78 191.29 30.05% 251.93 199.39 26.35% 256.35 167.37 53.16% 213.26 155.28 37.34%
EBITDA 50.57 33.91 49.13% 59.94 41.97 42.82% 52.27 37.30 40.13% 41.27 26.76 54.22%
EBIDTM 16.89% 15.06% 19.22% 17.39% 16.94% 18.22% 16.21% 14.70%
Other Income 7.82 12.19 -35.85% 22.51 1.32 1,605.30% 31.36 15.93 96.86% 8.15 32.62 -75.02%
Interest 0.31 0.23 34.78% 0.30 0.27 11.11% 0.28 0.23 21.74% 0.28 0.26 7.69%
Depreciation 8.18 7.47 9.50% 7.42 8.43 -11.98% 7.02 8.50 -17.41% 6.84 4.72 44.92%
PBT 49.90 38.40 29.95% 74.72 34.60 115.95% 76.34 44.50 71.55% 42.30 54.40 -22.24%
Tax 12.31 5.40 127.96% 19.26 9.31 106.87% 13.13 13.21 -0.61% 10.28 10.20 0.78%
PAT 37.59 32.99 13.94% 55.46 25.29 119.30% 63.20 31.29 101.98% 32.02 44.19 -27.54%
PATM 12.56% 14.65% 17.78% 10.48% 20.48% 15.29% 12.58% 24.28%
EPS 0.83 0.73 13.70% 1.22 0.56 117.86% 1.39 0.69 101.45% 0.71 0.98 -27.55%

Description Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var%
Net Sales 708.46 560.01 26.51% 681.85 586.13 16.33% 641.92 531.24 20.83% 590.62 500.03 18.12%
Expenses 582.70 450.37 29.38% 543.08 453.11 19.86% 506.24 417.29 21.32% 462.18 398.07 16.11%
EBITDA 125.75 109.64 14.69% 138.76 133.02 4.32% 135.68 113.95 19.07% 128.44 101.97 25.96%
EBIDTM 17.75% 19.58% 20.35% 22.70% 21.14% 21.45% 21.75% 20.39%
Other Income 16.52 16.53 -0.06% 27.85 4.80 480.21% 11.06 19.00 -41.79% 14.95 10.10 48.02%
Interest 3.44 4.84 -28.93% 2.67 3.16 -15.51% 2.63 1.63 61.35% 2.92 1.58 84.81%
Depreciation 22.74 21.05 8.03% 20.69 22.00 -5.95% 19.51 17.55 11.17% 20.44 13.66 49.63%
PBT 116.09 100.28 15.77% 143.26 112.66 27.16% 124.60 113.77 9.52% 120.02 96.83 23.95%
Tax 25.37 22.63 12.11% 38.19 29.69 28.63% 26.84 29.92 -10.29% 30.95 26.39 17.28%
PAT 90.73 77.64 16.86% 105.07 82.97 26.64% 97.76 83.85 16.59% 89.07 70.44 26.45%
PATM 12.81% 13.86% 15.41% 14.15% 15.23% 15.78% 15.08% 14.09%
EPS 2.00 1.73 15.61% 2.31 1.84 25.54% 2.13 1.84 15.76% 1.96 1.52 28.95%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Net Sales 1,174.39 853.27 655.20 658.29 599.55 433.42 424.16 294.66 215.84 358.13 405.59 Net Sales Growth 37.63% 30.23% -0.47% 9.80% 38.33% 2.18% 43.95% 36.52% -39.73% -11.70% Cost Of Goods Sold 639.95 478.93 394.44 377.59 337.91 245.41 236.34 169.35 112.37 178.18 218.16 Gross Profit 534.44 374.34 260.75 280.70 261.63 188.00 187.82 125.31 103.47 179.95 187.44 GP Margin 45.51% 43.87% 39.80% 42.64% 43.64% 43.38% 44.28% 42.53% 47.94% 50.25% 46.21% Total Expenditure 970.32 713.34 582.23 544.57 485.84 361.93 360.83 265.52 202.15 258.76 299.58 Power & Fuel Cost - 26.04 14.24 11.49 10.90 8.95 8.44 7.26 7.21 7.55 7.74 % Of Sales - 3.05% 2.17% 1.75% 1.82% 2.06% 1.99% 2.46% 3.34% 2.11% 1.91% Employee Cost - 77.19 56.09 60.46 54.64 48.51 46.33 45.86 39.77 26.13 23.65 % Of Sales - 9.05% 8.56% 9.18% 9.11% 11.19% 10.92% 15.56% 18.43% 7.30% 5.83% Manufacturing Exp. - 49.96 26.22 5.25 56.39 32.15 12.69 11.52 11.99 13.99 15.42 % Of Sales - 5.86% 4.00% 0.80% 9.41% 7.42% 2.99% 3.91% 5.56% 3.91% 3.80% General & Admin Exp. - 26.86 21.36 16.58 14.79 16.19 22.68 10.95 10.61 9.42 7.50 % Of Sales - 3.15% 3.26% 2.52% 2.47% 3.74% 5.35% 3.72% 4.92% 2.63% 1.85% Selling & Distn. Exp. - 45.79 53.97 59.37 8.56 10.37 34.30 20.58 20.20 23.48 21.52 % Of Sales - 5.37% 8.24% 9.02% 1.43% 2.39% 8.09% 6.98% 9.36% 6.56% 5.31% Miscellaneous Exp. - 8.56 15.89 13.84 2.64 0.34 0.04 0.00 0.00 0.00 21.52 % Of Sales - 1.00% 2.43% 2.10% 0.44% 0.08% 0.01% 0% 0% 0% 1.38% EBITDA 204.05 139.93 72.97 113.72 113.71 71.49 63.33 29.14 13.69 99.37 106.01 EBITDA Margin 17.37% 16.40% 11.14% 17.28% 18.97% 16.49% 14.93% 9.89% 6.34% 27.75% 26.14% Other Income 69.84 62.07 79.41 42.25 31.16 0.17 7.93 7.43 17.75 13.21 12.82 Interest 1.17 0.99 3.61 3.80 5.34 7.29 6.56 7.67 4.49 6.20 13.11 Depreciation 29.46 29.13 16.74 17.66 15.19 11.64 8.69 12.25 15.00 14.75 9.03 PBT 243.26 171.89 132.03 134.51 124.33 52.73 56.01 16.65 11.95 91.63 96.69 Tax 54.98 38.13 29.17 30.52 25.95 14.82 12.39 4.23 0.40 20.14 29.58 Tax Rate 22.60% 22.18% 22.09% 22.69% 20.87% 28.11% 22.12% 25.41% 3.35% 21.98% 30.59% PAT 188.27 133.76 102.87 103.99 98.38 37.90 43.62 12.43 11.55 71.49 67.11 PAT before Minority Interest 188.27 133.76 102.87 103.99 98.38 37.90 43.62 12.43 11.55 71.49 67.11 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 16.03% 15.68% 15.70% 15.80% 16.41% 8.74% 10.28% 4.22% 5.35% 19.96% 16.55% PAT Growth 40.75% 30.03% -1.08% 5.70% 159.58% -13.11% 250.93% 7.62% -83.84% 6.53% EPS 4.15 2.95 2.27 2.29 2.17 0.84 0.96 0.27 0.25 1.58 1.48

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Net Sales 2,622.85 2,177.41 1,852.14 1,490.84 1,376.18 1,134.21 1,000.07 912.69 767.16 893.33 796.69 Net Sales Growth 20.46% 17.56% 24.23% 8.33% 21.33% 13.41% 9.57% 18.97% -14.12% 12.13% Cost Of Goods Sold 1,143.75 1,038.12 921.36 716.81 595.05 567.83 498.01 523.13 458.74 509.69 445.44 Gross Profit 1,479.10 1,139.29 930.78 774.02 781.13 566.38 502.07 389.57 308.42 383.63 351.25 GP Margin 56.39% 52.32% 50.25% 51.92% 56.76% 49.94% 50.20% 42.68% 40.20% 42.94% 44.09% Total Expenditure 2,094.20 1,718.83 1,512.82 1,231.96 1,036.58 941.96 867.92 834.31 734.24 760.91 620.86 Power & Fuel Cost - 36.94 24.50 18.59 16.42 14.38 14.34 11.83 13.27 12.58 9.72 % Of Sales - 1.70% 1.32% 1.25% 1.19% 1.27% 1.43% 1.30% 1.73% 1.41% 1.22% Employee Cost - 293.64 239.37 220.30 197.32 168.42 159.07 147.75 149.70 122.42 72.61 % Of Sales - 13.49% 12.92% 14.78% 14.34% 14.85% 15.91% 16.19% 19.51% 13.70% 9.11% Manufacturing Exp. - 136.67 96.47 12.73 127.47 113.32 77.14 59.90 47.34 50.44 37.59 % Of Sales - 6.28% 5.21% 0.85% 9.26% 9.99% 7.71% 6.56% 6.17% 5.65% 4.72% General & Admin Exp. - 59.73 52.79 37.74 50.67 45.52 51.03 42.51 37.52 36.01 15.35 % Of Sales - 2.74% 2.85% 2.53% 3.68% 4.01% 5.10% 4.66% 4.89% 4.03% 1.93% Selling & Distn. Exp. - 127.31 133.19 119.05 33.54 32.15 68.36 49.14 27.66 29.77 34.47 % Of Sales - 5.85% 7.19% 7.99% 2.44% 2.83% 6.84% 5.38% 3.61% 3.33% 4.33% Miscellaneous Exp. - 26.42 45.14 106.73 16.10 0.34 -0.01 0.05 0.00 0.00 34.47 % Of Sales - 1.21% 2.44% 7.16% 1.17% 0.03% 0.00% 0.01% 0% 0% 0.71% EBITDA 528.63 458.58 339.32 258.88 339.60 192.25 132.15 78.38 32.92 132.42 175.83 EBITDA Margin 20.15% 21.06% 18.32% 17.36% 24.68% 16.95% 13.21% 8.59% 4.29% 14.82% 22.07% Other Income 70.38 50.42 59.31 41.85 6.69 0.33 4.62 8.47 18.85 12.72 12.23 Interest 11.66 11.20 9.13 8.45 7.99 8.75 9.66 10.22 6.78 10.16 16.05 Depreciation 83.38 74.27 51.85 44.78 36.15 26.66 22.80 26.84 30.09 28.13 16.13 PBT 503.97 423.53 337.65 247.51 302.16 157.17 104.31 49.80 14.90 106.85 155.88 Tax 121.35 108.63 72.33 60.70 63.63 36.42 23.87 14.00 3.56 24.11 43.92 Tax Rate 24.08% 25.65% 21.42% 24.52% 21.06% 23.17% 22.88% 28.11% 23.89% 22.56% 28.18% PAT 382.63 313.69 266.31 184.56 235.94 117.02 76.46 32.94 8.83 78.51 109.39 PAT before Minority Interest 380.59 314.89 265.32 186.81 238.54 120.75 80.44 35.80 11.33 82.74 111.96 Minority Interest -2.04 -1.20 0.99 -2.25 -2.60 -3.73 -3.98 -2.86 -2.50 -4.23 -2.57 PAT Margin 14.59% 14.41% 14.38% 12.38% 17.14% 10.32% 7.65% 3.61% 1.15% 8.79% 13.73% PAT Growth 21.51% 17.79% 44.29% -21.78% 101.62% 53.05% 132.12% 273.05% -88.75% -28.23% EPS 8.44 6.92 5.88 4.07 5.21 2.58 1.69 0.73 0.19 1.73 2.41

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Shareholder's Funds 1,222.70 1,111.32 784.67 599.72 505.63 470.57 428.97 418.88 422.70 358.18 Share Capital 45.32 45.32 40.93 40.93 40.93 40.93 40.93 40.93 53.43 53.43 Total Reserves 1,177.39 1,066.01 650.64 558.79 464.69 429.64 388.04 377.95 369.27 304.75 Non-Current Liabilities 20.89 17.00 14.41 23.93 24.79 18.39 17.09 17.30 0.31 0.50 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 4.47 3.18 1.86 2.11 1.47 1.36 1.08 0.96 0.00 0.00 Current Liabilities 304.73 240.91 190.39 137.26 79.73 133.39 111.22 109.59 111.19 168.43 Trade Payables 159.72 111.58 74.45 64.16 56.65 37.23 33.68 20.60 31.41 44.58 Other Current Liabilities 105.84 97.65 78.95 42.70 10.92 7.34 8.79 0.71 0.68 39.88 Short Term Borrowings 0.00 0.00 5.00 0.00 0.00 77.33 66.31 73.23 40.62 43.52 Short Term Provisions 39.16 31.68 31.99 30.40 12.15 11.50 2.45 15.04 38.49 40.45 Total Liabilities 1,548.32 1,369.23 989.47 760.91 610.15 622.35 557.28 545.77 534.20 527.11 Net Block 271.57 143.94 135.51 129.09 115.18 102.61 87.89 93.92 97.47 90.01 Gross Block 472.78 318.89 301.34 277.25 248.77 224.90 201.83 195.61 184.48 162.47 Accumulated Depreciation 201.20 174.95 165.83 148.16 133.59 122.28 113.94 101.69 87.01 72.45 Non Current Assets 568.33 431.10 375.75 369.32 355.73 339.98 324.78 329.16 330.16 158.45 Capital Work in Progress 0.00 3.90 0.00 0.00 0.00 0.00 0.00 0.36 0.00 0.00 Non Current Investment 265.75 265.75 236.07 236.07 236.07 236.07 236.07 234.29 231.44 67.62 Long Term Loans & Adv. 30.84 17.50 4.16 4.16 4.47 1.29 0.82 0.59 1.25 0.83 Other Non Current Assets 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 979.99 938.13 613.73 391.60 254.41 282.37 232.51 216.61 204.04 368.66 Current Investments 26.99 0.54 0.44 0.26 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 190.85 130.95 103.67 93.69 74.60 70.36 42.29 29.24 43.74 51.03 Sundry Debtors 370.17 305.49 246.78 168.93 161.87 177.83 168.87 154.80 133.41 124.63 Cash & Bank 312.23 440.26 224.05 105.61 3.35 1.80 0.71 2.56 3.13 167.54 Other Current Assets 79.74 7.17 12.06 1.91 14.58 32.38 20.62 30.01 23.76 25.46 Short Term Loans & Adv. 68.00 53.71 26.73 21.20 13.76 24.91 14.54 29.92 23.76 25.46 Net Current Assets 675.27 697.22 423.34 254.34 174.68 148.98 121.28 107.02 92.85 200.23 Total Assets 1,548.32 1,369.23 989.48 760.92 610.14 622.35 557.29 545.77 534.20 527.11

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Shareholder's Funds 2,065.05 1,745.16 1,202.27 886.50 636.01 542.48 470.86 433.43 454.32 379.76 Share Capital 45.32 45.32 40.93 40.93 40.93 40.93 40.93 40.93 53.43 53.43 Total Reserves 2,019.74 1,699.85 1,068.24 845.56 595.08 501.55 429.93 392.50 400.89 326.33 Non-Current Liabilities 205.20 84.33 57.05 23.70 24.15 17.14 15.64 16.07 -1.91 1.46 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 4.56 3.25 1.86 2.11 1.47 1.36 1.08 0.96 0.00 0.00 Current Liabilities 389.85 340.99 380.08 298.97 228.75 232.62 234.68 296.06 259.43 286.24 Trade Payables 268.28 230.60 200.08 168.66 110.33 106.07 77.83 161.78 118.98 107.02 Other Current Liabilities 70.62 42.20 96.80 79.69 58.86 20.90 10.08 0.71 0.68 39.88 Short Term Borrowings 29.09 41.59 41.29 18.74 18.84 99.91 117.41 109.71 87.89 82.19 Short Term Provisions 21.86 26.60 41.92 31.88 40.72 5.74 29.36 23.85 51.88 57.15 Total Liabilities 2,680.95 2,190.39 1,660.10 1,228.03 902.02 802.46 730.73 751.81 720.20 675.56 Net Block 775.94 486.31 428.31 309.36 302.72 269.73 279.38 266.98 269.65 165.90 Gross Block 1,193.49 828.26 726.26 551.92 565.39 506.26 495.35 456.49 429.47 297.78 Accumulated Depreciation 417.55 341.95 297.96 242.56 262.67 236.54 215.97 189.52 159.82 131.89 Non Current Assets 818.46 515.09 435.04 325.20 308.45 271.02 280.19 267.92 280.06 166.72 Capital Work in Progress 9.42 9.87 2.57 11.68 0.00 0.00 0.00 0.36 0.00 0.00 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 32.94 18.91 4.16 4.16 5.73 1.29 0.82 0.59 10.41 0.83 Other Non Current Assets 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 1,862.49 1,675.30 1,225.07 902.82 593.59 531.44 450.54 483.88 440.15 508.83 Current Investments 26.99 0.54 0.44 0.26 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 617.94 484.74 424.44 404.32 241.84 293.25 218.12 190.09 167.79 130.11 Sundry Debtors 453.18 416.85 394.78 271.95 243.35 176.60 176.91 247.58 217.29 183.45 Cash & Bank 673.58 714.96 349.26 212.18 93.73 33.54 39.88 25.16 35.30 185.27 Other Current Assets 90.80 22.74 24.36 14.11 14.66 28.06 15.63 21.05 19.76 10.01 Short Term Loans & Adv. 59.82 35.48 31.79 0.00 3.40 0.00 0.00 20.96 19.76 10.01 Net Current Assets 1,472.64 1,334.31 844.98 603.85 364.83 298.82 215.86 187.82 180.71 222.60 Total Assets 2,680.95 2,190.39 1,660.11 1,228.02 902.04 802.46 730.73 751.80 720.21 675.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Cash From Operating Activity 34.05 51.73 55.97 106.92 107.58 19.81 15.63 -13.62 64.76 112.03 PBT 171.89 132.03 134.51 124.33 52.73 56.01 16.65 11.95 91.63 96.69 Adjustment -16.40 10.91 -7.93 -8.82 19.17 11.57 20.00 12.50 8.82 17.75 Changes in Working Capital -82.68 -59.60 -38.77 11.62 46.17 -34.91 -16.33 -22.39 -15.35 28.53 Cash after chg. in Working capital 72.82 83.34 87.80 127.13 118.06 32.67 20.32 2.06 85.09 142.97 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -38.76 -31.62 -31.83 -20.21 -10.49 -12.86 -4.68 -15.69 -20.33 -30.94 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -114.22 -194.62 -128.06 8.87 -24.15 -20.20 -7.55 -7.69 -177.34 -29.14 Net Fixed Assets -149.99 -21.45 -24.09 -28.48 -23.87 -23.07 -5.86 -11.49 -22.01 -32.23 Net Investments -26.45 -29.78 -0.18 -0.26 0.00 0.00 -1.78 -2.85 -163.82 0.00 Others 62.22 -143.39 -103.79 37.61 -0.28 2.87 0.09 6.65 8.49 3.09 Cash from Financing Activity -26.21 210.02 70.86 -13.53 -81.87 0.96 -9.98 20.74 -51.83 51.28 Net Cash Inflow / Outflow -106.38 67.12 -1.23 102.26 1.55 0.56 -1.90 -0.57 -164.41 134.17 Opening Cash & Equivalents 148.31 81.19 82.42 3.35 1.80 0.55 2.45 3.13 167.54 33.37 Closing Cash & Equivalent 41.93 148.31 81.19 105.61 3.35 1.12 0.55 2.56 3.13 167.54

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Cash From Operating Activity 230.41 237.41 99.26 178.59 233.33 27.40 50.09 14.06 30.80 154.51 PBT 423.53 337.65 247.51 302.16 157.17 104.31 49.80 14.90 106.85 109.40 Adjustment 55.42 74.24 35.31 56.57 42.04 31.88 43.99 26.58 39.63 24.26 Changes in Working Capital -126.19 -111.47 -110.70 -131.61 59.12 -81.79 -36.23 -6.04 -88.14 20.27 Cash after chg. in Working capital 352.76 300.43 172.12 227.12 258.33 54.40 57.56 35.44 58.34 153.94 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -122.35 -63.01 -72.86 -48.53 -25.00 -27.00 -7.46 -21.37 -27.54 -0.89 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -140.84 -259.21 -84.39 -44.85 -59.58 -13.48 -38.81 -20.73 -123.01 -33.19 Net Fixed Assets -149.99 -21.45 -24.09 -28.48 -23.87 -23.07 -5.86 -11.49 -22.01 -32.23 Net Investments -26.45 -29.78 -0.18 -0.26 0.00 0.00 -1.78 -2.85 -163.82 0.00 Others 35.60 -207.98 -60.12 -16.11 -35.71 9.59 -31.17 -6.39 62.82 -0.96 Cash from Financing Activity -68.73 197.83 79.51 -15.29 -113.55 -20.78 3.38 -3.47 -57.75 16.99 Net Cash Inflow / Outflow 20.84 176.03 94.38 118.46 60.19 -6.86 14.67 -10.14 -149.96 138.32 Opening Cash & Equivalents 382.44 206.41 112.03 93.73 33.54 39.72 25.05 35.30 185.27 46.95 Closing Cash & Equivalent 403.28 382.44 206.41 212.18 93.73 32.85 39.72 25.16 35.30 185.27

Financial Ratios

Consolidated /

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Book Value (Rs.) 26.98 24.52 16.90 14.65 12.35 11.50 10.48 10.23 10.02 8.45 ROA 9.17% 8.72% 11.88% 14.35% 6.15% 7.40% 2.25% 2.14% 13.47% 14.85% ROE 11.46% 11.41% 16.11% 17.80% 7.77% 9.70% 2.93% 2.79% 18.91% 27.27% ROCE 14.81% 14.27% 19.91% 23.46% 11.39% 11.99% 4.92% 3.44% 22.45% 33.41% Fixed Asset Turnover 2.16 2.24 2.30 2.30 1.83 1.99 1.48 1.14 2.06 2.77 Receivable days 144.13 144.90 114.03 99.91 143.04 149.17 200.47 243.69 131.50 106.64 Inventory Days 68.65 61.56 54.14 50.83 61.04 48.47 44.31 61.71 48.29 47.98 Payable days 103.38 86.07 66.99 65.25 47.33 37.28 36.94 45.72 53.08 52.33 Cash Conversion Cycle 109.41 120.38 101.18 85.49 156.75 160.37 207.84 259.68 126.70 102.30 Total Debt/Equity 0.00 0.00 0.01 0.00 0.00 0.17 0.16 0.17 0.10 0.14 Interest Cover 174.98 37.54 36.44 24.26 8.23 9.54 3.17 3.66 15.77 8.37

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Book Value (Rs.) 45.57 38.51 27.10 21.66 15.54 13.25 11.50 10.59 10.79 8.97 ROA 12.93% 13.78% 12.94% 22.40% 14.17% 10.49% 4.83% 1.54% 11.86% 19.21% ROE 16.53% 18.59% 18.72% 31.33% 20.49% 15.88% 7.92% 2.59% 20.45% 45.15% ROCE 22.40% 22.89% 23.82% 39.76% 25.57% 18.51% 10.60% 3.99% 23.16% 44.64% Fixed Asset Turnover 2.26 2.62 2.42 2.49 2.12 2.00 1.92 1.73 2.46 2.85 Receivable days 69.35 72.63 78.56 67.57 67.57 64.51 84.88 110.59 81.87 80.88 Inventory Days 87.89 81.36 97.65 84.73 86.10 93.32 81.63 85.14 60.86 53.30 Payable days 87.70 85.31 93.88 85.57 45.09 38.48 55.10 65.56 54.58 56.06 Cash Conversion Cycle 69.54 68.67 82.33 66.73 108.58 119.35 111.40 130.17 88.15 78.13 Total Debt/Equity 0.01 0.02 0.04 0.02 0.03 0.18 0.25 0.25 0.19 0.23 Interest Cover 38.80 37.99 30.31 38.84 18.97 11.80 5.87 3.20 11.52 10.72

Top Investors:

orbimed asia iv mauritius fvci limited

massachusetts institute of technology

uti-healthcare fund

kotak mahindra trustee co ltd a/c kotak special opportunities fund

investor education and protection fund (iepf)

Annual Reports:

News Update:

Marksans Pharma’s arm gets marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution
30th May 2025, 10:41 AM

Relonchem has received marketing authorization from UK Medicines & Healthcare Products Regulatory Agency
Read More
Marksans Pharma reports 17% rise in Q4 consolidated net profit
20th May 2025, 15:19 PM

The total consolidated income of the company increased by 25.75% at Rs 724.98 crore for Q4FY25
Read More
Marksans Pharma’s arm gets marketing authorization for Sennosides 7.5 mg Tablets
19th May 2025, 16:09 PM

The company’s arm received Marketing Authorization from UK Medicines & Healthcare Products Regulatory Agency
Read More
Marksans Pharma’s arm receives marketing authorization for Gabapentin
15th May 2025, 11:00 AM

The company has received this authorization from UK Medicines & Healthcare Products Regulatory Agency
Read More
USFDA completes cGMP inspection at manufacturing facility of Marksans Pharma’s arm
28th Apr 2025, 12:40 PM

On conclusion of the inspection, the Subsidiary has received 1 inspectional observation in Form 483
Read More
Marksans Pharma’s Goa facility gets Australian TGA’s nod to manufacture pharmaceutical formulations
20th Mar 2025, 14:51 PM

The products will be manufactured at the facility in Goa, India and marketed & distributed in Australian markets through the company’s subsidiary
Read More
Marksans Pharma’s arm receives marketing authorization for Baclofen
19th Mar 2025, 16:40 PM

Relonchem has received Marketing Authorization from UK MHRA
Read More

Marksans Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524404 | NSE: MARKSANS

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Marksans Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524404 | NSE: MARKSANS

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: